Citi Raises Roivant Sciences (ROIV) PT to $35 Following Positive Phase 2 Brepocitinib Data

Group 1 - Roivant Sciences Ltd. (NASDAQ:ROIV) is considered a promising low-cost stock, with multiple firms raising their price targets following positive Phase 2 data for brepocitinib in cutaneous sarcoidosis [1][2][3] - Citi raised its price target for Roivant Sciences to $35 from $26 while maintaining a Buy rating, citing the drug's growth potential and integrating revenue projections into its financial model [1][4] - H.C. Wainwright also increased its price target to $33 from $26, characterizing the Phase 2 data as impressive and adding this indication to its valuation model [2] - Bank of America raised its price target to $26 from $22 with a Neutral rating, noting that the FQ3 2026 results were in line and highlighting the positive Phase 2 topline results of brepocitinib [3]